Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TransMedics (TMDX) Gross Margin (2018 - 2025)

TransMedics has reported Gross Margin over the past 8 years, most recently at 58.11% for Q4 2025.

  • Quarterly results put Gross Margin at 58.11% for Q4 2025, down 110.0% from a year ago — trailing twelve months through Dec 2025 was 59.92% (up 56.0% YoY), and the annual figure for FY2025 was 59.92%, up 56.0%.
  • Gross Margin for Q4 2025 was 58.11% at TransMedics, down from 58.8% in the prior quarter.
  • Over the last five years, Gross Margin for TMDX hit a ceiling of 81.76% in Q4 2021 and a floor of 55.94% in Q3 2024.
  • Median Gross Margin over the past 5 years was 63.2% (2021), compared with a mean of 65.19%.
  • Biggest five-year swings in Gross Margin: surged 1845bps in 2021 and later plummeted -1577bps in 2022.
  • TransMedics' Gross Margin stood at 81.76% in 2021, then fell by -19bps to 65.99% in 2022, then dropped by -11bps to 59.04% in 2023, then increased by 0bps to 59.21% in 2024, then fell by -2bps to 58.11% in 2025.
  • The last three reported values for Gross Margin were 58.11% (Q4 2025), 58.8% (Q3 2025), and 61.38% (Q2 2025) per Business Quant data.